NeoImmuneTech Balance Sheet Health
Financial Health criteria checks 6/6
NeoImmuneTech has a total shareholder equity of ₩58.8B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩72.6B and ₩13.8B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩54.50b |
| Equity | ₩58.83b |
| Total liabilities | ₩13.79b |
| Total assets | ₩72.62b |
Financial Position Analysis
Short Term Liabilities: A950220's short term assets (₩59.7B) exceed its short term liabilities (₩12.2B).
Long Term Liabilities: A950220's short term assets (₩59.7B) exceed its long term liabilities (₩1.6B).
Debt to Equity History and Analysis
Debt Level: A950220 is debt free.
Reducing Debt: A950220 has no debt compared to 5 years ago when its debt to equity ratio was 1.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A950220 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A950220 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 21.6% each year.